Fortis Healthcare has scheduled a joint meeting with analysts and investors on September 4, 2026, at 1:00 pm IST. The session will also feature management from IHH Healthcare Berhad.

Meeting details

The interaction is structured as a virtual group call to provide updates on recent business developments. No unpublished price-sensitive information (UPSI) will be discussed during the session.

Such meetings serve as a structured forum for the company to engage directly with the investment community, providing an opportunity for stakeholders to seek clarity on operational matters.

Dial-in details

Participants can join via the following numbers:

• India: +91 22 6280 1307 or +91 22 7115 8208
• UK (Toll Free): 0 808 101 1573
• US (Toll Free): 1 866 746 2133
• Singapore (Toll Free): 800 101 2045
• Hong Kong (Toll Free): 800 964 448
• Malaysia (Toll Free): 1 800 814 080

A replay of the call will be available from September 4 to September 11, 2026, via +91 22 7194 5757 using playback ID 15861.

The Delhi High Court has directed a forensic audit into the dissipation of shareholding by Fortis Healthcare Limited’s erstwhile promoters and the subsequent change in control of the company.

The company disclosed the order on September 1, 2026, noting that the court did not impose any liability, penalty, or fine on the listed entity. The investigation stems from applications filed by Daiichi Sankyo Company, Limited.

Court Order Details

A single judge bench of the Delhi High Court passed the order on August 31, 2026. The mandate requires a factual enquiry into:

• The dissipation of the shareholding of the Singh Brothers, the company’s erstwhile promoters.
• The subsequent change in control of the company.
• The role of relevant stakeholders, including banks, financial institutions, erstwhile promoters, their controlled entities, and the company.

Legal Position and Impact

Fortis Healthcare stated it was neither a party to the original dispute nor a judgment debtor in the execution proceedings. The company emphasized that the forensic audit direction is purely investigative and does not result in any determination or fastening of liability upon the entity.

The management is reviewing the judgment with legal counsels to evaluate the appropriate course of action under applicable law. The company reaffirmed its commitment to corporate governance and regulatory compliance.